Summit Therapeutics receives FDA fast-track decision for new antibiotic
8th Jul 2015 12:04
Drug discovery and development company Summit Therapeutics has received approval from the US and Food Drug Administration (FDA) for its novel antibiotic. The FDA granted fast-track designation for the SMT19969 antibiotic which treats both duchenne muscular dystrophy and C. difficile infection (CDI).
Read moreSummit Therapeutics first-quarter pre-tax loss widens
11th Jun 2015 12:28
Drug discovery and development company Summit Therapeutics posted a 52.6% widening in its first-quarter pre-tax loss, pointing to the cost of listing on the NASDAQ and higher research and development costs. The pre-tax losses came in at $5.8m compared with $3.8m in the same period last year. In the
Read moreSummit chief buys 30,000 shares
30th Jul 2014 16:48
AIM-listed drug developer Summit, which develops therapies for Duchenne Muscular Dystrophy and C. difficile infection, on Wednesday said its chief executive Glyn Edwards had acquired 30,000 shares. The 104.5p-a-share deal cost Edwards £31,350 and took his stake in the group to 233,333 shares. The
Read moreSummit Corp. reports progress with DMD trial, but next phase delayed
21st May 2014 12:43
Shares in Summit Corporation suffered a fall despite giving a generally positive report of the first phase of its Duchenne Muscular Dystrophy (DMD) trial which has examined the safety and tolerance of SMT C1100. The decline may be linked to a delay in the next patient study, which is expected to no
Read moreSector movers: AstraZeneca, Shire lift pharma stocks on upbeat guidance
14th Jan 2014 15:22
Decent gains from AstraZeneca and Shire gave the pharmaceuticals sector a boost on Tuesday as both firms gave confident outlooks. At the JP Morgan Healthcare Conference in San Francisco, AstraZeneca Chief Executive Pascal Soriot said he expects the company to return to growth sooner than analysts c
Read moreMonday broker round-up UPDATE
18th Nov 2013 08:10
AGA Rangemaster: N+1 Singer raises its target price from 150p to 175p and keeps a buy recommendation. APR Energy: Jefferies cuts target price from 1300p to 1260p retaining a buy recommendation. Atkins (WS): LIberum Capital increases target price from 1300p to 1400p maintaining a buy recommendation
Read moreThursday broker round-up UPDATE
22nd Aug 2013 07:25
Aggreko: RBC Capital reduces target price from 1850p to 1680p, while its neutral rating remains unchanged. Aviva: JP Morgan raises target price from 393p to 436p and retains an overweight rating. BHP Billiton: Canaccord Genuity takes target price from 1950p to 2050p maintaining a hold recommendati
Read moreWednesday broker round-up UPDATE
3rd Jul 2013 09:16
Aberdeen Asset Management: Bank of America reduces target price from 410p to 360p maintaining an underperform rating. ARM Holdings: UBS upgrades to buy from neutral, keeps target price at 970p. Cineworld: Investec ups target price from 347p to 360p and keeps a buy recommendation. N+1 Singer moves
Read moreRefocused Summit targets new funding
11th Apr 2013 09:02
AIM-listed biotech group Summit Corporation has narrowed the focus of its research programmes to two key assets, which both made encouraging progress in clinical trials, the company said. Chief Executive Glyn Edwards, who was appointed in April last year, curtailed other research activities to pre
Read moreSummit study augurs well for Alzheimer's sufferers
11th Mar 2013 09:18
Shares in AIM-listed drug development company Summit rose on Monday after the company unveiled encouraging results from a study investigating the impacts of a treatment on neurodegenerative diseases. The company reported that it had presented new data from its OGA (O-linked N-acetylglucosaminidase
Read moreSummit Corp. forms advisory board to aid development of drug
13th Feb 2013 13:32
Summit Corp., an AIM-listed drug discovery and development company, has formed an advisory board to support the scientific and clinical development of its utrophin modulator programme for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy (DMD). The board will be made up of six
Read moreSummit wins multi-million pound drug funding
22nd Oct 2012 09:40
Summit, a UK drug discovery company, said it had been awarded four million pounds to support clinical development of a new C. difficult antibiotic The money from charitable foundation the Wellcome Trust will be used to develop Summit's SMT 19969 drug through to clinical proof of concept studies.
Read moreSummit successfully tests muscle dystrophy drug
10th Oct 2012 09:08
Shares in drug developer Summit Corporation rocketed on Wednesday after it announced positive results in tests for its new Duchenne Muscular Dystrophy (DMD) drug. DMD is a fatal muscle wasting disease for which there is currently no cure. The firm announced positive top-line results from a Phase 1
Read moreContract wins round-up: Summit, Pinnacle, Eckoh
11th Sep 2012 09:49
UK drug discovery company Summit has signed a technology licensing agreement with US pharmaceuticals colossus, Bristol-Myers Squibb. The US firm will use use Summit's proprietary Seglin technology to identify and develop drug candidates for up to ten targets across multiple therapeutic areas. Summi
Read moreSummit Corp rises on technology agreement
11th Sep 2012 08:20
Shares in Summit Corporation, an Oxford based drug developer, soared 20 per cent on Tuesday after it announced it has entered a technology licence agreement with Bristol-Myers Squibb Company. Under the agreement, Bristol-Myers will use Summit's Seglin technology to identify and develop drug candida
Read more